Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$4.94 USD
+0.59 (13.56%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $4.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRME 4.94 +0.59(13.56%)
Will PRME be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for PRME
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PRME
Crossed Above 50 Day Moving Average appears for PRME after 13.56% move
Is PRME about to break its pattern? NR7 shows up after declining 4.19%
Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
Intellia Therapeutics price target lowered by $5 at Wedbush, here's why
PRME Fell Below 50 Day Moving Average on October 29